Search

Your search keyword '"Capitain O"' showing total 159 results
Start Over Author "Capitain O"
159 results on '"Capitain O"'

4. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Author

Adenis, A., Alessio, A., Aouakli, A., Azzedine, A., Bedjaoui, A., Bidault, A., Blanchi, A., Botton, A., Cadier-Lagnes, A., Fatisse, A., Gagnaire, A., Gilbert, A., Gueye, A., Hollebecque, A., Lemaire, A., Mahamat, A., Marre, A., Patenotte, A., Rotenberg, A., Roussel, A., Thirot-Bidault, A., Votte, A., Weber, A., Zaanan, A., Dupont-Gossart, A.C., Villing, A.L., Queuniet, A.M., Coudert, B., Denis, B., Garcia, B., Lafforgue, B., Landi, B., Leduc, B., Linot, B., Paillot, B., Rhein, B., Winkfield, B., Barberis, C., Becht, C., Belletier, C., Berger, C., Bineau, C., Borel, C., Brezault, C., Buffet, C., Cornila, C., Couffon, C., De La Fouchardière, C., Giraud, C., Lecaille, C., Lepere, C., Lobry, C., Locher, C., Lombard-Bohas, C., Paoletti, C., Platini, C., Rebischung, C., Sarda, C., Vilain, C., Briac-Levaché, C., Auby, D., Baudet-Klepping, D., Bechade, D., Besson, D., Cleau, D., Festin, D., Gargot, D., Genet, D., Goldfain, D., Luet, D., Malka, D., Peré-Vergé, D., Pillon, D., Sevin-Robiche, D., Smith, D., Soubrane, D., Tougeron, D., Zylberait, D., Carola, E., Cuillerier, E., Dorval Danquechin, E., Echinard, E., Janssen, E., Maillard, E., Mitry, E., Norguet-Monnereau, E., Suc, E., Terrebonne, E., Zrihen, E., Pariente, E.A., Almaric, F., Audemar, F., Bonnetain, F., Desseigne, F., Dewaele, F., Di Fiore, F., Ghiringhelli, F., Husseini, F., Khemissa, F., Kikolski, F., Morvan, F., Petit-Laurent, F., Riot, F., Subtil, F., Zerouala-Boussaha, F., Caroli-Bosc, F.X., Boilleau-Jolimoy, G., Bordes, G., Cavaglione, G., Coulanjon, G., Deplanque, G., Gatineau-Saillant, G., Goujon, G., Medinger, G., Roquin, G., Brixi-Benmansour, H., Castanie, H., Lacroix, H., Maechel, H., Perrier, H., Salloum, H., Senellart, H., Baumgaertner, I., Cumin, I., Graber, I., Trouilloud, I., Boutin, J., Butel, J., Charneau, J., Cretin, J., Dauba, J., Deguiral, J., Egreteau, J., Ezenfis, J., Forestier, J., Goineau, J., Lacourt, J., Lafon, J., Martin, J., Meunier, J., Moreau, J., Provencal, J., Taieb, J., Thaury, J., Tuaillon, J., Vergniol, J., Villand, J., Vincent, J., Volet, J., Bachet, J.B., Barbare, J.C., Souquet, J.C., Grangé, J.D., Dor, J.F., Paitel, J.F., Jouve, J.L., Raoul, J.L., Cheula, J.M., Gornet, J.M., Sabate, J.M., Vantelon, J.M., Vaillant, J.N., Aucouturier, J.P., Barbieux, J.P., Herr, J.P., Lafargue, J.P., Lagasse, J.P., Latrive, J.P., Plachot, J.P., Ramain, J.P., Robin, J.P., Spano, J.P., Douillard, J.Y., Beerblock, K., Bouhier-Leporrier, K., Slimane Fawzi, K., Cany, L., Chone, L., Dahan, L., Gasnault, L., Rob, L., Stefani, L., Wander, L., Baconnier, M., Ben Abdelghani, M., Benchalal, M., Blasquez, M., Carreiro, M., Charbit, M., Combe, M., Duluc, M., Fayolle, M., Gignoux, M., Giovannini, M., Glikmanas, M., Mabro, M., Mignot, M., Mornet, M., Mousseau, M., Mozer, M., Pauwels, M., Pelletier, M., Porneuf, M., Ramdani, M., Schnee, M., Tissot, M., Zawadi, M., Clavero-Fabri, M.C., Gouttebel, M.C., Kaminsky, M.C., Galais, M.P., Abdelli, N., Barrière, N., Bouaria, N., Bouarioua, N., Delas, N., Gérardin, N., Hess-Laurens, N., Stremsdoerfer, N., Berthelet, O., Boulat, O., Capitain, O., Favre, O., Amoyal, P., Bergerault, P., Burtin, P., Cassan, P., Chatrenet, P., Chiappa, P., Claudé, P., Couzigou, P., Feydy, P., Follana, P., Geoffroy, P., Godeau, P., Hammel, P., Laplaige, P., Lehair, P., Martin, P., Novello, P., Pantioni, P., Pienkowski, P., Pouderoux, P., Prost, P., Ruszniewski, P., Souillac, P., Texereau, P., Thévenet, P., Haineaux, P.A., Benoit, R., Coriat, R., Lamy, R., Mackiewicz, R., Beorchia, S., Chaussade, S., Hiret, S., Jacquot, S., Lavau Denes, S., Montembault, S., Nahon, S., Nasca, S., Nguyen, S., Oddou-Lagraniere, S., Pesque-Penaud, S., Fratte, S.P., Chatellier, T., Mansourbakht, T., Morin, T., Walter, T., Boige, V., Bourgeois, V., Derias, V., Guérin-Meyer, V., Hautefeuille, V., Jestin Le Tallec, V., Lorgis, V., Quentin, V., Sebbagh, V., Veuillez, V., Adhoute, X., Coulaud, X., Becouarn, Y., Coscas, Y., Courouble, Y., Le Bricquir, Y., Molin, Y., Rinaldi, Y., Lam, Y.H., Ladhib, Z., Aparicio, Thomas, Ducreux, Michel, Faroux, Roger, Barbier, Emilie, Manfredi, Sylvain, Lecomte, Thierry, Etienne, Pierre-Luc, Bedenne, Laurent, Bennouna, Jaafar, Phelip, Jean-Marc, François, Eric, Michel, Pierre, Legoux, Jean-Louis, Gasmi, Mohamed, Breysacher, Gilles, Rougier, Philippe, De Gramont, Aimery, Lepage, Come, Bouché, Olivier, and Seitz, Jean-François

Published
2018
Full Text
View/download PDF

6. 1296MO PRODIGE 29-UCGI 26(NEOPAN): A phase III randomised trial comparing chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)

Author

Ducreux, M.P., primary, Desgrippes, R., additional, Rinaldi, Y., additional, Di Fiore, F., additional, Guimbaud, R., additional, Follana, P., additional, Bachet, J-B., additional, Vanelslander, P., additional, Lecomte, T., additional, Capitain, O., additional, Parzy, A., additional, Bolliet, M., additional, Etienne, P-L., additional, Forestier, J., additional, El Hajbi, F., additional, Bignon Bretagne, A.L., additional, Ly Lebrun, V., additional, De Sousa Carvalho, N., additional, Texier, M., additional, and Bouche, O., additional

Published
2022
Full Text
View/download PDF

10. Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (Observatoire dédié au Cancer Bretagne / Pays de la Loire)

Author

Metges, J. P., Lebot, M. A., Faroux, R., Riaud, F., Gamelin, E., Capitain, O., Guérin Meyer, V., Leynia, P., Douillard, J. Y., Senellart, H., Rochard, S., Louvigné, C., Campion, L., Dupuis, O., Grollier, C., Achour, N. A., Person, B., Raoul, J. L., Boucher, E., Bertrand, C., Ramée, J. F., Guivarch, L., Etienne, P. L., Roussel, S., Desclos, H., Julien, M. N., Labarre, M. I., Klein, V., Bessard, R., Stampfli, C., Royet, F., Faycal, J., Gouva, S., Le Bihan, G., Couturier, M., Gourlaouen, A., Bertholom, C., Porneuf, M., Jobard, E., Peguet, E., Grasset, D., Bouret, J. F., Bicheler, V., Ulvoas, A., Miglianico, L., Chouzenoux, C., Deguiral, P., Derenne, L., Martin, D., Langlet, P. Michel, Bodin, C., Rossi, V., Barré, S., Cojocarasu, O., Naveau Ploux, C., Vidal, A. M., Cumin, I., Egreteau, J., Brouard, A., Matysiak Budnik, T., Thomaré, P., Le Bris Michel, A. S., Piriou, G., Largeau, R., Elhannani, C., Crespeau, E., Suberville, F., Bourgeois, H., Riche, C., Lagadec, D. Déniel, Marhuenda, F., and Grudé, F.

Published
2014
Full Text
View/download PDF

13. 481P Evaluation of serum mid-infrared spectroscopy as new prognostic marker for bevacizumab-based chemotherapy in first-line treatment of metastatic colorectal cancer

Author

Chautard, R., primary, Léger, J., additional, Bouche, O., additional, Borg, C., additional, Douillard, J-Y., additional, Manfredi, S., additional, Terrebonne, E., additional, Capitain, O., additional, Spano, J-P., additional, Caulet, M., additional, Raoul, W., additional, Guéguinou, M., additional, Hérault, O., additional, Ferru, A., additional, Pobel, C.J., additional, Sire, O., additional, and Lecomte, T., additional

Published
2021
Full Text
View/download PDF

15. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

Author

Guigay, J, Auperin, A, Fayette, J, Saada-Bouzid, E, Lafond, C, Taberna, M, Geoffrois, L, Martin, L, Capitain, O, Cupissol, D, Castanie, H, Vansteene, D, Schafhausen, P, Johnson, A, Even, C, Sire, C, Duplomb, S, Evrard, C, Delord, JP, Laguerre, B, Zanetta, S, Chevassus-Clement, C, Fraslin, A, Louat, F, Sinigaglia, L, Keilholz, U, Bourhis, J, Mesia, R, Gallego, O, López Pousa A., and Vazquez Fernandez, Silvia

Abstract

Background Results from a phase 2 trial of the TPEx chemotherapy regimen (docetaxel-platinum-cetuximab) showed promising results, with a median overall survival of 14.0 months in first-line recurrent or metastatic head and neck squamous-cell carcinoma (HNSCC). We therefore aimed to compare the efficacy and safety of the TPEx regimen with the standard of care EXTREME regimen (platinum-fluorouracil-cetuximab) in this setting. Methods This was a multicentre, open-label, randomised, phase 2 trial, done in 68 centres (cancer centres, university and general hospitals, and private clinics) in France, Spain, and Germany. Eligible patients were aged 18-70 years with histologically confirmed recurrent or metastatic HNSCC unsuitable for curative treatment; had at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1; and had an Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less. Participants were randomly assigned (1:1) using the TenAlea website by investigators or delegated clinical research associates to the TPEx regimen or the EXTREME regimen, with minimisation by ECOG performance status, type of disease evolution, previous cetuximab treatment, and country. The TPEx regimen consisted of docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2), both intravenously on day 1, and cetuximab on days 1, 8, and 15 (intravenously 400 mg/m(2) on day 1 of cycle 1 and 250 mg/m(2) weekly subsequently). Four cycles were repeated every 21 days with systematic granulocyte colony-stimulating factor (G-CSF) support at each cycle. In case of disease control after four cycles, intravenous cetuximab 500 mg/m(2) was continued every 2 weeks as maintenance therapy until progression or unacceptable toxicity. The EXTREME regimen consisted of fluorouracil 4000 mg/m(2) on day 1-4, cisplatin 100 mg/m(2) on day 1, and cetuximab on days 1, 8, and 15 (400 mg/m(2) on day 1 of cycle 1 and 250 mg/m(2) weekly subsequently) all delivered intravenously. Six cycles were delivered every 21 days followed by weekly 250 mg/m(2) cetuximab as maintenance therapy in case of disease control. G-CSF support was not mandatory per the protocol in the EXTREME regimen. The primary endpoint was overall survival in the intention-to-treat population; safety was analysed in all patients who received at least one dose of chemotherapy or cetuximab. Enrolment is closed and this is the final analysis. This study is registered at ClinicalTrials.gov, NCT02268695. Findings Between Oct 10, 2014, and Nov 29, 2017, 541 patients were enrolled and randomly assigned to the two treatment regimens (271 to TPEx, 270 to EXTREME). Two patients in the TPEx group had major deviations in consent forms and were not included in the final analysis. Median follow-up was 34.4 months (IQR 26.6-44.8) in the TPEx group and 30.2 months (25.5-45.3) in the EXTREME group. At data cutoff, 209 patients had died in the TPEx group and 218 had died in the EXTREME group. Overall survival did not differ significantly between the groups (median 14.5 months [95% CI 12.5-15.7] in the TPEx group and 13.4 months [12.2-15.4] in the EXTREME group; hazard ratio 0.89 [95% CI 0.74-1.08]; p=0.23). 214 (81%) of 263 patients in the TPEx group versus 246 (93%) of 265 patients in the EXTREME group had grade 3 or worse adverse events during chemotherapy (p

Published
2021

16. 1617P PRODIGE 29-UCGI 26 (NEOPAN): Quality of life results of a phase III randomised trial comparing chemotherapy with folfirinox (FFX) or gemcitabine (gem) in locally advanced pancreatic carcinoma (LAPC)

Author

Ducreux, M.P., Desgrippes, R., Rinaldi, Y., Di Fiore, F., Guimbaud, R., Evesque, L., Bachet, J-B., Vanelslander, P., Lecomte, T., Capitain, O., Parzy, A., Bolliet, M., Etienne, P.L., Forestier, J., El Hajbi, F., Bignon Bretagne, A.L., Ly Lebrun, V., De Sousa Carvalho, N., Texier, M., and Bouche, O.

Published
2023
Full Text
View/download PDF

21. 63MO TG4001 therapeutic vaccination combined with PD-L1 blocker avelumab remodels the tumor microenvironement (TME) and drives antitumor responses in human papillomavirus (HPV)+ malignancies

Author

Le Tourneau, C., primary, Cassier, P., additional, Rolland, F., additional, Salas, S., additional, Limacher, J-M., additional, Capitain, O., additional, Lantz, O., additional, Lalanne, A., additional, Ekwegbara, C., additional, Tavernaro, A., additional, Makhloufi, H., additional, Bendjama, K., additional, and Delord, J-P., additional

Published
2020
Full Text
View/download PDF

23. Évaluation d’un pronostic clinique de 2 mois chez des patients atteints d’un cancer du sein : les premiers résultats de l’étude Pronopall...

Author

Bourgeois, H. P., primary, Traoré, S., additional, Solal-Celigny, P., additional, Dupuis, O., additional, Maillart, P., additional, Capitain, O., additional, Delva, R., additional, Soulie, P., additional, Marcq, M., additional, Boucher, E., additional, Ganem, G., additional, Bourbouloux, E., additional, Baudon, J., additional, Kaassis, M., additional, Zinger, M., additional, Lafond, C., additional, Berger, V., additional, Mussault, P., additional, Ingrand, P., additional, and Grude, F, additional

Published
2012
Full Text
View/download PDF

24. Étude de phase 1 d’escalade de dose d’irradiation avec modulation d’intensité et boost intégré simultané dans la chimioradiothérapie pelvienne des cancers du bas et moyen rectum métastatiques synchrones

Author

Lizée, T., primary, Seegers, V., additional, Blanchecotte, J., additional, Rio, E., additional, Capitain, O., additional, Guérin-Meyer, V., additional, Legouté, F., additional, Gonzalez-Moya, A., additional, Calais, G., additional, Autret, D., additional, Mahé, M.-A., additional, and Paumier, A., additional

Published
2019
Full Text
View/download PDF

25. Personalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) patients aged 70 or over: ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials

Author

Guigay, J., primary, Auperin, A., additional, Mertens, C., additional, Even, C., additional, Geoffrois, L., additional, Cupissol, D., additional, Rolland, F., additional, Sire, C., additional, Fayette, J., additional, Peyrade, F., additional, Blot, E., additional, Debourdeau, P., additional, Bozec, L., additional, Capitain, O., additional, Pointreau, Y., additional, Brard, C., additional, Michel, C., additional, Schwob, D., additional, Ortholan, C., additional, and Le Caer, H., additional

Published
2019
Full Text
View/download PDF

26. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Author

Pivot, Xavier, primary, Romieu, Gilles, additional, Debled, Marc, additional, Pierga, Jean-Yves, additional, Kerbrat, Pierre, additional, Bachelot, Thomas, additional, Lortholary, Alain, additional, Espié, Marc, additional, Fumoleau, Pierre, additional, Serin, Daniel, additional, Jacquin, Jean-Philippe, additional, Jouannaud, Christelle, additional, Rios, Maria, additional, Abadie-Lacourtoisie, Sophie, additional, Venat-Bouvet, Laurence, additional, Cany, Laurent, additional, Catala, Stéphanie, additional, Khayat, David, additional, Gambotti, Laetitia, additional, Pauporté, Iris, additional, Faure-Mercier, Celine, additional, Paget-Bailly, Sophie, additional, Henriques, Julie, additional, Grouin, Jean Marie, additional, Piprot, C, additional, Cals, L, additional, Chaigneau, L, additional, Demarchi, F, additional, N'Guyen, T, additional, Stein, U, additional, Villanueva, C, additional, Bréau, JL, additional, Chouahnia, AK, additional, Saintigny, P, additional, Boué, F, additional, deSaint-Hilaire, P, additional, Guimont, I, additional, Grossat, N, additional, Valenza, B, additional, Lévy, E, additional, Médioni, J, additional, Delbaldo, C, additional, Grenier, J, additional, Pouessel, D, additional, Lavau-Denès, S, additional, Falandry, C, additional, Fournel-Fédérico, C, additional, Freyer, G, additional, Tartas, S, additional, Trillet-Lenoir, V, additional, Bons, F, additional, Auclerc, G, additional, Chièze, S, additional, Raban, N, additional, Tournigand, C, additional, Trager-Maury, S, additional, Bousquet, G, additional, Cuvier, C, additional, Giacchetti, S, additional, Hocini, A, additional, LeMaignan, C, additional, Misset, JL, additional, Avenin, D, additional, Beerblock, C, additional, Gligorov, J, additional, Rivera, P, additional, Roché, H, additional, Bougnoux, P, additional, Hajjaji, N, additional, Capitain, O, additional, Delva, R, additional, Maillart, P, additional, Soulié, P, additional, Bonnefoi, H, additional, Durand, M, additional, Madranges, N, additional, Mauriac, L, additional, Chollet, P, additional, Dillies, AF, additional, Durando, X, additional, Ferrière, JP, additional, Mouret-Reynier, C, additional, Nabholtz, JM, additional, Van Praagh, I, additional, Cottu, P, additional, Diéras, V, additional, Durieux, A, additional, Galotte, M, additional, Girre, V, additional, Henry, S, additional, Iurisci, I, additional, Jouve, M, additional, Laurence, V, additional, Mignot, L, additional, Piperno-Neumann, S, additional, Tresca, P, additional, Coudert, B, additional, Ferrant, E, additional, Mayer, F, additional, Vanneuville, AC, additional, Bonneterre, J, additional, Servent, V, additional, Vanlemmens, L, additional, Vennin, P, additional, Guastalla, JP, additional, Biron, P, additional, Dupuy-Brousseau, L, additional, Lancry, L, additional, Ray-Coquard, I, additional, Rebattu, P, additional, Trédan, O, additional, Extra, JM, additional, Rousseau, F, additional, Tarpin, C, additional, Fabbro, M, additional, Luporsi, E, additional, Uwer, L, additional, Weber, B, additional, Berton-Rigaud, D, additional, Bourbouloux, E, additional, Campone, M, additional, Ferrero, JM, additional, Follana, P, additional, Largillier, R, additional, Mari, V, additional, Costa, B, additional, Curé, H, additional, Eymard, JC, additional, Jovenin, N, additional, Lebrun, D, additional, Meunier, J, additional, Yazbek, G, additional, Gedoin, D, additional, Laguerre, B, additional, Lefeuvre, C, additional, Vauléon, E, additional, Chevrier, A, additional, Guillemet, C, additional, Leheurteur, M, additional, Rigal, O, additional, Tennevet, I, additional, Veyret, C, additional, Brain, E, additional, Guiterrez, M, additional, Mefti-Lacheraf, F, additional, Petit, T, additional, Dalenc, F, additional, Gladieff, L, additional, André, F, additional, Delaloge, S, additional, Domont, J, additional, Ezenfis, J, additional, Spielmann, M, additional, Guillet, P, additional, Boulanger, V, additional, Provençal, J, additional, Stefani, L, additional, Alliot, C, additional, Ré, D, additional, Bellaiche-Miccio, C, additional, Boutan-Laroze, G, additional, Vanica, R, additional, Dion, P, additional, Sadki-Benaoudia, G, additional, Marti, A, additional, Villing, AL, additional, Slama, B, additional, Dutel, JL, additional, Nguyen, S, additional, Saad, R, additional, Arsène, O, additional, Merad-Boudia, Z, additional, Orfeuvre, H, additional, Egreteau, J, additional, Goudier, MJ, additional, Lamy, R, additional, Leduc, B, additional, Sarda, C, additional, Salles, B, additional, Agostini, C, additional, Cauvin, I, additional, Dufresne, A, additional, Mangold, M, additional, Lebouvier-Sadot, S, additional, Audhuy, B, additional, Barats, JC, additional, Cluet-Dennetière, S, additional, Zylberait, D, additional, Netter, G, additional, Gautier-Felizot, L, additional, Cojean-Zelek, I, additional, Plantade, A, additional, Vignot, S, additional, Guardiola, E, additional, Marti, P, additional, deHartingh, I, additional, Diab, R, additional, Dietmann, A, additional, Ruck, S, additional, Portois, C, additional, Oddou-Lagranière, S, additional, Campos-Gazeau, F, additional, Bourcier, A, additional, Priou, F, additional, Geay, JF, additional, Mayeur, D, additional, Gabez, P, additional, ElAmarti, R, additional, Combe, M, additional, Raichon-Patru, P, additional, Amsalhem, P, additional, Dauba, J, additional, Paraiso, D, additional, Guinet, F, additional, Duvert, B, additional, Litor, M, additional, Kara-Slimane, F, additional, Bichoffe, A, additional, Denizon, N, additional, Soyer, P, additional, Morvan, F, additional, Van-Hulst, S, additional, Vincent, L, additional, Alleaume, C, additional, Ibanez-Martin, P, additional, Youssef, A, additional, Tadrist, Z, additional, Carola, E, additional, Pourny, C, additional, Toccanier, JF, additional, Al-Aukla, N, additional, Mahour-Bacha, K, additional, Salvat, J, additional, Nouyrigat, P, additional, Clippe, S, additional, Gouttebel, MC, additional, Vedrine, L, additional, Clavreul, G, additional, Collard, O, additional, Mille, D, additional, Goubely, Y, additional, Hervé, R, additional, Kirscher, S, additional, Plat, F, additional, Delecroix, V, additional, Ligeza-Poisson, V, additional, Coeffic, D, additional, Fric, D, additional, Garnier, C, additional, Leyronnas, C, additional, Kreitman, T, additional, Teissier, E, additional, Martin, P, additional, Rohart deCordoue, S, additional, ElKouri, C, additional, Ramée, JF, additional, Laporte, C, additional, Bernard, O, additional, Altwegg, T, additional, Darut-Jouve, A, additional, Dujols, JP, additional, Darloy, F, additional, Giraud, C, additional, Pottier-Kyndt, V, additional, Achour, N, additional, Drony, S, additional, Moriceau, M, additional, Sarrazin, C, additional, Legueul, JC, additional, Mandet, J, additional, Besson, D, additional, Hardy-Bessard, AC, additional, Cretin, J, additional, Houyau, P, additional, Achille, E, additional, Genêt, D, additional, Thévenot, H, additional, Moran-Ribon, A, additional, Pavlovitch, JM, additional, Ardisson, P, additional, Moullet, I, additional, Couderc, B, additional, Fichet, V, additional, Burki, F, additional, Auliard, A, additional, Levaché, CB, additional, Cailleux, P, additional, Schaeffer, F, additional, Albin, N, additional, Sévin-Robiche, D, additional, Domas, J, additional, Ellis, S, additional, Montcuquet, P, additional, Baumont, GA, additional, Bégue, M, additional, Gréget, S, additional, Ratoanina, JL, additional, Vanoli, A, additional, Bielsa, C, additional, Bonichon-Lamichhane, M, additional, Jaubert, D, additional, Laharie-Mineur, H, additional, Alcaraz, L, additional, Legouffe, E, additional, Bourgeois, H, additional, Cartron, G, additional, Denis, F, additional, Dupuis, O, additional, Ganem, G, additional, Roche-Forestier, S, additional, Delzenne, L, additional, Chirat, E, additional, Baticle, JL, additional, Béguier, E, additional, Jacquot, S, additional, Janssen, E, additional, Lauché, H, additional, LeRol, A, additional, Chantelard, JP, additional, L'Helgoualc'h, GA, additional, Antoine, EC, additional, Kanoui, A, additional, Llory, JF, additional, Vannetzel, JM, additional, Vignoud, J, additional, Bruna, C, additional, Facchini, T, additional, Moutel-Corviole, K, additional, Voloch, A, additional, Ghoul, A, additional, Loiseau, D, additional, Barbet, N, additional, Dohollou, N, additional, and Yakendji, K, additional

Published
2019
Full Text
View/download PDF

27. PRODIGE 29-UCGI 26(NEOPAN): A randomised trial of chemotherapy with folfirinox or gemcitabine in locally advanced pancreatic carcinoma (PC)

Author

Ducreux, M.P., primary, Desgrippes, R., additional, Texier, M., additional, Di Fiore, F., additional, Vanelslander, P., additional, Capitain, O., additional, Guimbaud, R., additional, Forestier, J., additional, El Hajbi, F., additional, Follana, P., additional, Parzy, A., additional, Baba Hamed, N., additional, Rinaldi, Y., additional, Brotelle, T., additional, Pignon, J.-P., additional, Jouffroy, C., additional, Dahan, L., additional, and Bouche, O., additional

Published
2018
Full Text
View/download PDF

28. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Author

Aparicio, Thomas, primary, Ducreux, Michel, additional, Faroux, Roger, additional, Barbier, Emilie, additional, Manfredi, Sylvain, additional, Lecomte, Thierry, additional, Etienne, Pierre-Luc, additional, Bedenne, Laurent, additional, Bennouna, Jaafar, additional, Phelip, Jean-Marc, additional, François, Eric, additional, Michel, Pierre, additional, Legoux, Jean-Louis, additional, Gasmi, Mohamed, additional, Breysacher, Gilles, additional, Rougier, Philippe, additional, De Gramont, Aimery, additional, Lepage, Come, additional, Bouché, Olivier, additional, Seitz, Jean-François, additional, Adenis, A., additional, Alessio, A., additional, Aouakli, A., additional, Azzedine, A., additional, Bedjaoui, A., additional, Bidault, A., additional, Blanchi, A., additional, Botton, A., additional, Cadier-Lagnes, A., additional, Fatisse, A., additional, Gagnaire, A., additional, Gilbert, A., additional, Gueye, A., additional, Hollebecque, A., additional, Lemaire, A., additional, Mahamat, A., additional, Marre, A., additional, Patenotte, A., additional, Rotenberg, A., additional, Roussel, A., additional, Thirot-Bidault, A., additional, Votte, A., additional, Weber, A., additional, Zaanan, A., additional, Dupont-Gossart, A.C., additional, Villing, A.L., additional, Queuniet, A.M., additional, Coudert, B., additional, Denis, B., additional, Garcia, B., additional, Lafforgue, B., additional, Landi, B., additional, Leduc, B., additional, Linot, B., additional, Paillot, B., additional, Rhein, B., additional, Winkfield, B., additional, Barberis, C., additional, Becht, C., additional, Belletier, C., additional, Berger, C., additional, Bineau, C., additional, Borel, C., additional, Brezault, C., additional, Buffet, C., additional, Cornila, C., additional, Couffon, C., additional, De La Fouchardière, C., additional, Giraud, C., additional, Lecaille, C., additional, Lepere, C., additional, Lobry, C., additional, Locher, C., additional, Lombard-Bohas, C., additional, Paoletti, C., additional, Platini, C., additional, Rebischung, C., additional, Sarda, C., additional, Vilain, C., additional, Briac-Levaché, C., additional, Auby, D., additional, Baudet-Klepping, D., additional, Bechade, D., additional, Besson, D., additional, Cleau, D., additional, Festin, D., additional, Gargot, D., additional, Genet, D., additional, Goldfain, D., additional, Luet, D., additional, Malka, D., additional, Peré-Vergé, D., additional, Pillon, D., additional, Sevin-Robiche, D., additional, Smith, D., additional, Soubrane, D., additional, Tougeron, D., additional, Zylberait, D., additional, Carola, E., additional, Cuillerier, E., additional, Dorval Danquechin, E., additional, Echinard, E., additional, Janssen, E., additional, Maillard, E., additional, Mitry, E., additional, Norguet-Monnereau, E., additional, Suc, E., additional, Terrebonne, E., additional, Zrihen, E., additional, Pariente, E.A., additional, Almaric, F., additional, Audemar, F., additional, Bonnetain, F., additional, Desseigne, F., additional, Dewaele, F., additional, Di Fiore, F., additional, Ghiringhelli, F., additional, Husseini, F., additional, Khemissa, F., additional, Kikolski, F., additional, Morvan, F., additional, Petit-Laurent, F., additional, Riot, F., additional, Subtil, F., additional, Zerouala-Boussaha, F., additional, Caroli-Bosc, F.X., additional, Boilleau-Jolimoy, G., additional, Bordes, G., additional, Cavaglione, G., additional, Coulanjon, G., additional, Deplanque, G., additional, Gatineau-Saillant, G., additional, Goujon, G., additional, Medinger, G., additional, Roquin, G., additional, Brixi-Benmansour, H., additional, Castanie, H., additional, Lacroix, H., additional, Maechel, H., additional, Perrier, H., additional, Salloum, H., additional, Senellart, H., additional, Baumgaertner, I., additional, Cumin, I., additional, Graber, I., additional, Trouilloud, I., additional, Boutin, J., additional, Butel, J., additional, Charneau, J., additional, Cretin, J., additional, Dauba, J., additional, Deguiral, J., additional, Egreteau, J., additional, Ezenfis, J., additional, Forestier, J., additional, Goineau, J., additional, Lacourt, J., additional, Lafon, J., additional, Martin, J., additional, Meunier, J., additional, Moreau, J., additional, Provencal, J., additional, Taieb, J., additional, Thaury, J., additional, Tuaillon, J., additional, Vergniol, J., additional, Villand, J., additional, Vincent, J., additional, Volet, J., additional, Bachet, J.B., additional, Barbare, J.C., additional, Souquet, J.C., additional, Grangé, J.D., additional, Dor, J.F., additional, Paitel, J.F., additional, Jouve, J.L., additional, Raoul, J.L., additional, Cheula, J.M., additional, Gornet, J.M., additional, Sabate, J.M., additional, Vantelon, J.M., additional, Vaillant, J.N., additional, Aucouturier, J.P., additional, Barbieux, J.P., additional, Herr, J.P., additional, Lafargue, J.P., additional, Lagasse, J.P., additional, Latrive, J.P., additional, Plachot, J.P., additional, Ramain, J.P., additional, Robin, J.P., additional, Spano, J.P., additional, Douillard, J.Y., additional, Beerblock, K., additional, Bouhier-Leporrier, K., additional, Slimane Fawzi, K., additional, Cany, L., additional, Chone, L., additional, Dahan, L., additional, Gasnault, L., additional, Rob, L., additional, Stefani, L., additional, Wander, L., additional, Baconnier, M., additional, Ben Abdelghani, M., additional, Benchalal, M., additional, Blasquez, M., additional, Carreiro, M., additional, Charbit, M., additional, Combe, M., additional, Duluc, M., additional, Fayolle, M., additional, Gignoux, M., additional, Giovannini, M., additional, Glikmanas, M., additional, Mabro, M., additional, Mignot, M., additional, Mornet, M., additional, Mousseau, M., additional, Mozer, M., additional, Pauwels, M., additional, Pelletier, M., additional, Porneuf, M., additional, Ramdani, M., additional, Schnee, M., additional, Tissot, M., additional, Zawadi, M., additional, Clavero-Fabri, M.C., additional, Gouttebel, M.C., additional, Kaminsky, M.C., additional, Galais, M.P., additional, Abdelli, N., additional, Barrière, N., additional, Bouaria, N., additional, Bouarioua, N., additional, Delas, N., additional, Gérardin, N., additional, Hess-Laurens, N., additional, Stremsdoerfer, N., additional, Berthelet, O., additional, Boulat, O., additional, Capitain, O., additional, Favre, O., additional, Amoyal, P., additional, Bergerault, P., additional, Burtin, P., additional, Cassan, P., additional, Chatrenet, P., additional, Chiappa, P., additional, Claudé, P., additional, Couzigou, P., additional, Feydy, P., additional, Follana, P., additional, Geoffroy, P., additional, Godeau, P., additional, Hammel, P., additional, Laplaige, P., additional, Lehair, P., additional, Martin, P., additional, Novello, P., additional, Pantioni, P., additional, Pienkowski, P., additional, Pouderoux, P., additional, Prost, P., additional, Ruszniewski, P., additional, Souillac, P., additional, Texereau, P., additional, Thévenet, P., additional, Haineaux, P.A., additional, Benoit, R., additional, Coriat, R., additional, Lamy, R., additional, Mackiewicz, R., additional, Beorchia, S., additional, Chaussade, S., additional, Hiret, S., additional, Jacquot, S., additional, Lavau Denes, S., additional, Montembault, S., additional, Nahon, S., additional, Nasca, S., additional, Nguyen, S., additional, Oddou-Lagraniere, S., additional, Pesque-Penaud, S., additional, Fratte, S.P., additional, Chatellier, T., additional, Mansourbakht, T., additional, Morin, T., additional, Walter, T., additional, Boige, V., additional, Bourgeois, V., additional, Derias, V., additional, Guérin-Meyer, V., additional, Hautefeuille, V., additional, Jestin Le Tallec, V., additional, Lorgis, V., additional, Quentin, V., additional, Sebbagh, V., additional, Veuillez, V., additional, Adhoute, X., additional, Coulaud, X., additional, Becouarn, Y., additional, Coscas, Y., additional, Courouble, Y., additional, Le Bricquir, Y., additional, Molin, Y., additional, Rinaldi, Y., additional, Lam, Y.H., additional, and Ladhib, Z., additional

Published
2018
Full Text
View/download PDF

29. Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective method

Author

Boisdron-Celle, M., primary, Metges, J., additional, Capitain, O., additional, Faroux, R., additional, Stampfli, C., additional, Ferec, M., additional, Laplaige, P., additional, Lecomte, T., additional, Matysiak-Budnik, T., additional, Senellart, H., additional, Campone, M., additional, Morel, A., additional, and Gamelin, E., additional

Published
2018
Full Text
View/download PDF

31. Traitement des mucites radio- et chimio-induites par laser de basse énergie en cancérologie ORL : résultats de l’essai de phase III randomisé multicentrique « Laser mucite ORL »

Author

Legouté, F., primary, Bensadoun, R.-J., additional, Pointreau, Y., additional, Seegers, V., additional, Schick, U., additional, Capitain, O., additional, Caron, D., additional, Martin, L., additional, Prévost, A., additional, Lang, P., additional, and Jadaud, E., additional

Published
2017
Full Text
View/download PDF

32. The ELAN-ONCOVAL (ELderly heAd and Neck cancer-Oncology eValuation) study: Evaluation of the feasibility of a suited geriatric assessment for use by oncologists to classify patients as fit or unfit

Author

Mertens, C., primary, Le Caer, H., additional, Ortholan, C., additional, Blot, E., additional, Even, C., additional, Rousselot, H., additional, Peyrade, F., additional, Sire, C., additional, Cupissol, D., additional, Pointreau, Y., additional, Debourdeau, P., additional, Rolland, F., additional, Fayette, J., additional, Capitain, O., additional, Sun, X., additional, Debbah, M., additional, Schwob, D., additional, Boulahssass, R., additional, Aupérin, A., additional, and Guigay, J., additional

Published
2017
Full Text
View/download PDF

33. Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study

Author

Bourgeois, H., primary, Grudé, F., additional, Solal-Céligny, P., additional, Dupuis, O., additional, Voog, E., additional, Ganem, G., additional, Denis, F., additional, Zinger, M., additional, Juhel-Voog, L., additional, Lafond, C., additional, Maillart, P., additional, Capitain, O., additional, Delva, R., additional, Soulié, P., additional, Abadie-Lacourtoisie, S., additional, Guérin-Meyer, V., additional, Morin-Meschin, M.E., additional, Commer, J.M., additional, Gangler, A., additional, d’Aillières, B., additional, Zannetti, A., additional, Bourbouloux, E., additional, Berton-Rigault, D., additional, Lebouvier-Sadot, S., additional, Kaassis, M., additional, Baudon, J., additional, Lam, Y.H., additional, Bizieux, A., additional, Marcq, M., additional, Edeline, J., additional, Le Du, F., additional, Lefeuvre, C., additional, Deguiral, P., additional, Delecroix, V., additional, Blot, E., additional, Egreteau, J., additional, Goudier, M.J., additional, Lamy, R., additional, Ferec, M., additional, Artignan, X., additional, Corbinais, S., additional, Morel, H., additional, Hardy-Bessard, A.C., additional, Alleaume, C., additional, Naudeix, E., additional, Cojocarasu, O., additional, Metges, J.P., additional, Riché, C., additional, Gamelin, E., additional, Déniel-Lagadec, D., additional, Marhuenda, F., additional, Ingrand, P., additional, and Douillard, J.Y., additional

Published
2017
Full Text
View/download PDF

35. 1110O - Personalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) patients aged 70 or over: ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials

Author

Guigay, J., Auperin, A., Mertens, C., Even, C., Geoffrois, L., Cupissol, D., Rolland, F., Sire, C., Fayette, J., Peyrade, F., Blot, E., Debourdeau, P., Bozec, L., Capitain, O., Pointreau, Y., Brard, C., Michel, C., Schwob, D., Ortholan, C., and Le Caer, H.

Published
2019
Full Text
View/download PDF

36. Valeur pronostique du volume tumoral métabolique sur la TEP au (18F)-fluorodésoxyglucose préthérapeutique pour le cancer de l’œsophage localisé

Author

Paumier, A., primary, Marquis, A., additional, Trémolières, P., additional, Lacombe, M., additional, Capitain, O., additional, Septans, A.-L., additional, Peyraga, G., additional, Gustin, P., additional, Vénara, A., additional, Ménager, É., additional, Visvikis, D., additional, Couturier, O., additional, Rio, E., additional, and Hatt, M., additional

Published
2016
Full Text
View/download PDF

39. Des marges extensives sont-elles nécessaires pour la radiothérapie du cancer de l’œsophage ?

Author

Peyraga, G., primary, Capitain, O., additional, Rousseau, D., additional, Rio, E., additional, Septans, A.-L., additional, Baton, O., additional, Marquis, A., additional, Trémolières, P., additional, Gustin, P., additional, Ménager, É., additional, Branger, F., additional, Bressolette, M., additional, Deutsch, É., additional, and Paumier, A., additional

Published
2015
Full Text
View/download PDF

40. Sites de récidive après radiothérapie conformationnelle avec modulation d’intensité des carcinomes épidermoïdes des voies aérodigestives supérieures

Author

Yossi, S., primary, El Alouani, C., additional, Pointreau, Y., additional, Laccourreye, L., additional, Capitain, O., additional, Gustin, P., additional, Peyraga, G., additional, Septans, A.-L., additional, Jadaud, É., additional, Vinchon-Petit, S., additional, Cellier, P., additional, Autret, D., additional, and Tuchais, C., additional

Published
2015
Full Text
View/download PDF

41. 1050PD - The ELAN-ONCOVAL (ELderly heAd and Neck cancer-Oncology eValuation) study: Evaluation of the feasibility of a suited geriatric assessment for use by oncologists to classify patients as fit or unfit

Author

Mertens, C., Le Caer, H., Ortholan, C., Blot, E., Even, C., Rousselot, H., Peyrade, F., Sire, C., Cupissol, D., Pointreau, Y., Debourdeau, P., Rolland, F., Fayette, J., Capitain, O., Sun, X., Debbah, M., Schwob, D., Boulahssass, R., Aupérin, A., and Guigay, J.

Published
2017
Full Text
View/download PDF

43. A Triple Combination Tailored Therapy (Folfiri-Cetuximab) for Safe Dose Intensification: A Multicenter Phase II Proof-Of-Concept Study.

Author

Capitain, O., primary, Metges, J.P., additional, Boisdron-Celle, M., additional, Adenis, A., additional, Raoul, J.L., additional, Lecomte, T., additional, Lam, Y., additional, Faroux, R., additional, Masliah, C., additional, Poirier, A.L., additional, Berger, V., additional, Morel, A., additional, and Gamelin, E., additional

Published
2014
Full Text
View/download PDF

44. Évaluation en pratique courante de l’association bevacizumab-FOLFIRI en première ligne chez des patients atteints d’un cancer colorectal métastatique non résécable traités en 2006: focus sur patients réséqués et oncogériatrie

Author

Metges, J. P., primary, Lebot, M. A., additional, Faroux, R., additional, Riaud, F., additional, Gamelin, E., additional, Capitain, O., additional, Guérin Meyer, V., additional, Leynia, P., additional, Douillard, J. Y., additional, Senellart, H., additional, Rochard, S., additional, Louvigné, C., additional, Campion, L., additional, Dupuis, O., additional, Grollier, C., additional, Achour, N. A., additional, Person, B., additional, Raoul, J. L., additional, Boucher, E., additional, Bertrand, C., additional, Ramée, J. F., additional, Guivarch, L., additional, Etienne, P. L., additional, Roussel, S., additional, Desclos, H., additional, Julien, M. N., additional, Labarre, M. I., additional, Klein, V., additional, Bessard, R., additional, Stampfli, C., additional, Royet, F., additional, Faycal, J., additional, Gouva, S., additional, Le Bihan, G., additional, Couturier, M., additional, Gourlaouen, A., additional, Bertholom, C., additional, Porneuf, M., additional, Jobard, E., additional, Peguet, E., additional, Grasset, D., additional, Bouret, J. F., additional, Bicheler, V., additional, Ulvoas, A., additional, Miglianico, L., additional, Chouzenoux, C., additional, Deguiral, P., additional, Derenne, L., additional, Martin, D., additional, Langlet, P. Michel, additional, Bodin, C., additional, Rossi, V., additional, Barré, S., additional, Cojocarasu, O., additional, Naveau Ploux, C., additional, Vidal, A. M., additional, Cumin, I., additional, Egreteau, J., additional, Brouard, A., additional, Matysiak Budnik, T., additional, Thomaré, P., additional, Le Bris Michel, A. S., additional, Piriou, G., additional, Largeau, R., additional, Elhannani, C., additional, Crespeau, E., additional, Suberville, F., additional, Bourgeois, H., additional, Riche, C., additional, Lagadec, D. Déniel, additional, Marhuenda, F., additional, and Grudé, F., additional

Published
2014
Full Text
View/download PDF

46. Abstract P3-13-07: A-TaXel: Multicenter phase II combination of bevacizumab (A) with weekly paclitaxel (Ta) and capecitabine (Xel) in first line treatment for patients with triple negative metastatic or locally advanced breast cancer (TNMBC), a GINECO study

Author

Ferrero, J-M, primary, Hardy-Bessard, A-C, additional, Capitain, O, additional, Lortholary, A, additional, Salles, B, additional, Follana, P, additional, Herve, R, additional, Deblock, M, additional, Dauba, J, additional, Atlassi, M, additional, and Largillier, R, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results